Kezar Life Sciences (NASDAQ:KZR) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Kezar Life Sciences (NASDAQ:KZR – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright also issued estimates for Kezar Life Sciences’ Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at […]
More Stories
iShares Short Duration Bond Active ETF (BATS:NEAR) Hits New 1-Year High – What’s Next?
iShares Short Duration Bond Active ETF (BATS:NEAR – Get Free Report) hit a new 52-week high on Monday . The...
Nuveen ESG Large-Cap Growth ETF (BATS:NULG) Reaches New 1-Year High – Should You Buy?
Nuveen ESG Large-Cap Growth ETF (BATS:NULG – Get Free Report) reached a new 52-week high during trading on Monday ....
Scout24 (ETR:G24) Sets New 52-Week High – Here’s Why
Scout24 SE (ETR:G24 – Get Free Report) shares hit a new 52-week high during trading on Monday . The company...
iShares MSCI USA Value Factor ETF (BATS:VLUE) Hits New 12-Month High – Time to Buy?
iShares MSCI USA Value Factor ETF (BATS:VLUE – Get Free Report)’s share price hit a new 52-week high during mid-day...
iShares MSCI Chile ETF (BATS:ECH) Reaches New 12-Month Low – Time to Sell?
iShares MSCI Chile ETF (BATS:ECH – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on...
Wacker Chemie (ETR:WCH) Sets New 12-Month Low – Should You Sell?
Wacker Chemie AG (ETR:WCH – Get Free Report)’s share price hit a new 52-week low on Monday . The stock...